Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Alkermes ( (ALKS) ) has shared an announcement.
Alkermes, Inc. has fully prepaid and terminated its Amended and Restated Credit Agreement with Morgan Stanley and other lenders, avoiding any early termination penalties aside from customary breakage costs. This move effectively releases all liens on collateral associated with the credit agreement, potentially impacting the company’s financial flexibility and operational strategies.
More about Alkermes
Alkermes plc is a biopharmaceutical company that develops innovative medicines in the fields of neuroscience and oncology. The company’s primary products and services focus on delivering treatments related to mental health and cancer, catering to a broad market in the healthcare industry.
YTD Price Performance: 8.40%
Average Trading Volume: 1,785,680
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.87B
Learn more about ALKS stock on TipRanks’ Stock Analysis page.
